Ładuje się......
Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?
INTRODUCTION: Receptor tyrosine kinases (RTKs) are validated targets for oncology drug discovery and several RTK antagonists have been approved for the treatment of human malignancies. Nonetheless, the discovery and development of RTK antagonists has lagged behind the discovery and development of ag...
Zapisane w:
| 1. autor: | |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2011
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3083243/ https://ncbi.nlm.nih.gov/pubmed/21532939 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/17460441.2011.547468 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|